Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel Free CSBR Stock Alerts

Champions Oncology (CSBR) Competitors

Champions Oncology logo
$5.07 -0.01 (-0.20%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$5.04 -0.03 (-0.59%)
As of 08/14/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CSBR vs. TKNO, OABI, QTRX, QSI, and CDXS

Should you buy Champions Oncology stock or one of its competitors? Champions Oncology's main competitors and comparable companies include Alpha Teknova (TKNO), OmniAb (OABI), Quanterix (QTRX), Quantum-Si (QSI), and Codexis (CDXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Champions Oncology compare to Alpha Teknova?

Champions Oncology (NASDAQ:CSBR) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Champions Oncology has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 47.0% of Champions Oncology shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Champions Oncology and Champions Oncology both had 1 articles in the media. Champions Oncology's average media sentiment score of 1.91 beat Alpha Teknova's score of 1.44 indicating that Champions Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Champions Oncology Very Positive
Alpha Teknova Positive

Alpha Teknova has a consensus price target of $7.50, indicating a potential upside of 2.88%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Champions Oncology has a net margin of -1.87% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-1.87% -27.48% -3.84%
Alpha Teknova -38.37%-24.94%-16.53%

Champions Oncology has higher revenue and earnings than Alpha Teknova. Champions Oncology is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$59.42M1.19-$1.17M-$0.08N/A
Alpha Teknova$40.52M9.65-$17.26M-$0.31N/A

Summary

Champions Oncology beats Alpha Teknova on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to OmniAb?

OmniAb (NASDAQ:OABI) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

OmniAb has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Champions Oncology has a net margin of -1.87% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
OmniAb-115.12% -16.59% -14.82%
Champions Oncology -1.87%-27.48%-3.84%

In the previous week, OmniAb had 11 more articles in the media than Champions Oncology. MarketBeat recorded 12 mentions for OmniAb and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat OmniAb's score of 0.77 indicating that Champions Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
OmniAb Positive
Champions Oncology Very Positive

72.1% of OmniAb shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Champions Oncology has higher revenue and earnings than OmniAb. Champions Oncology is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmniAb$38.46M12.73-$64.78M-$0.36N/A
Champions Oncology$59.42M1.19-$1.17M-$0.08N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OmniAb
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

OmniAb beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

86.5% of Quanterix shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 47.0% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Quanterix had 10 more articles in the media than Champions Oncology. MarketBeat recorded 11 mentions for Quanterix and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Quanterix's score of -0.44 indicating that Champions Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
Quanterix Neutral
Champions Oncology Very Positive

Champions Oncology has lower revenue, but higher earnings than Quanterix. Champions Oncology is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quanterix$138.90M0.88-$107.15M-$2.63N/A
Champions Oncology$59.42M1.19-$1.17M-$0.08N/A

Quanterix has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Champions Oncology has a net margin of -1.87% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Quanterix-80.25% -26.09% -19.03%
Champions Oncology -1.87%-27.48%-3.84%

Quanterix presently has a consensus price target of $3.50, indicating a potential upside of 35.14%. Given Quanterix's stronger consensus rating and higher possible upside, equities analysts clearly believe Quanterix is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Quanterix beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Quantum-Si has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

In the previous week, Quantum-Si had 10 more articles in the media than Champions Oncology. MarketBeat recorded 11 mentions for Quantum-Si and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Quantum-Si's score of 0.42 indicating that Champions Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
Quantum-Si Neutral
Champions Oncology Very Positive

Champions Oncology has higher revenue and earnings than Quantum-Si. Champions Oncology is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quantum-Si$2.44M66.02-$101.34M-$0.46N/A
Champions Oncology$59.42M1.19-$1.17M-$0.08N/A

Quantum-Si presently has a consensus price target of $1.00, suggesting a potential upside of 35.17%. Given Quantum-Si's stronger consensus rating and higher possible upside, equities analysts clearly believe Quantum-Si is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quantum-Si
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Champions Oncology has a net margin of -1.87% compared to Quantum-Si's net margin of -6,138.26%. Champions Oncology's return on equity of -27.48% beat Quantum-Si's return on equity.

Company Net Margins Return on Equity Return on Assets
Quantum-Si-6,138.26% -45.05% -41.10%
Champions Oncology -1.87%-27.48%-3.84%

39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Champions Oncology beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Codexis?

Champions Oncology (NASDAQ:CSBR) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Codexis has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, Codexis had 10 more articles in the media than Champions Oncology. MarketBeat recorded 11 mentions for Codexis and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Codexis' score of 0.27 indicating that Champions Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Champions Oncology Very Positive
Codexis Neutral

Champions Oncology has a net margin of -1.87% compared to Codexis' net margin of -39.55%. Champions Oncology's return on equity of -27.48% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-1.87% -27.48% -3.84%
Codexis -39.55%-74.36%-23.58%

Codexis has a consensus target price of $5.00, indicating a potential upside of 220.51%. Given Codexis' stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 47.0% of Champions Oncology shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Champions Oncology has higher earnings, but lower revenue than Codexis. Champions Oncology is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$59.42M1.19-$1.17M-$0.08N/A
Codexis$70.39M2.43-$43.97M-$0.34N/A

Summary

Codexis beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSBR vs. The Competition

Export
MetricChampions OncologyLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$70.37M$9.56B$7.03B$13.07B
Dividend YieldN/A1.46%2.57%10.64%
P/E Ratio-63.3860.31271.5425.40
Price / Sales1.19105.43673.88125.76
Price / Cash348.2126.1175.7053.27
Price / Book17.4837.5012.926.21
Net Income-$1.17M$56.66B$3.45B$347.71M
7 Day Performance-2.31%0.29%1.16%1.08%
1 Month Performance-13.18%2.08%2.17%1.87%
1 Year Performance-23.59%17.23%62.38%20.79%

Champions Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSBR
Champions Oncology
0.3906 of 5 stars		$5.07
-0.2%		N/A-23.6%$70.37M$59.42MN/A143
TKNO
Alpha Teknova
1.8166 of 5 stars		$5.61
+1.6%		$7.00
+24.8%		+55.4%$295.95M$40.52MN/A240
OABI
OmniAb
0.7857 of 5 stars		$2.03
+1.5%		$3.00
+47.8%		+68.2%$289.57M$18.67MN/A7
QTRX
Quanterix
1.6009 of 5 stars		$3.76
+1.3%		$4.00
+6.4%		-43.3%$174.76M$138.90MN/A460
QSI
Quantum-Si
2.6595 of 5 stars		$0.76
-1.2%		$1.00
+32.2%		-32.7%$166.67M$2.44MN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Why acquisitions are reshaping the gold mining sector right now
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel